NEWS ROUNDUP
Sworning in of Mansukh Mandaviya, Health Minister of India
Mansukh Mandaviya sworn in as Union Health Minister
Takeda, Frazier Healthcare partner to launch HilleVax
CII, SII to expand vaccination across small towns, rural areas
Mansukh Mandaviya is the new health minister of India, replacing Dr Harsh Vardhan. Mandaviya’s portfolio assumes utmost significance as the country is amid the coronavirus pandemic. Mandaviya is among the seven ministers of states who have been promoted and given a cabinet rank in today’s cabinet rejig by Prime Minister Narendra Modi. He is a Rajya Sabha MP from Gujarat. Mandaviya will also be in charge of the Ministry of Chemical and Fertilizers. He earlier served as minister of state for ports, shipping and waterways and minister of state for chemical and fertilisers.
Takeda has granted a license to HilleVax
Mandaviya is born in a middle-class farmer family in a village called Hanol, Palitana taluka of Saurashtra’s region Bhavnagar district. He became the youngest MLA at the age of 28 years in 2002. He studied veterinary science at the Gujarat Agricultural University’s Dantiwada and later completed his masters in political science.
outside of Japan. Takeda will retain
The Confederation of Indian Industry (CII) has partnered with Serum Institute of India (SII) to accelerate vaccination in partnership with industry, including healthcare providers. The vaccine drive will target communities in India’s small towns and rural areas to ensure wide coverage. As part of the pan-India vaccine demand aggregation exercise, CII surveyed with a response from over 3000 companies in 196 cities. This identified a requirement of over seven million single-dose vaccines. CII is now mapping the vaccination need requirement state-wise and setting up vaccination camps along with its members focusing on reaching Tier II / III cities and rural areas.
for
the
exclusive
development
and
commercialisation rights to its norovirus vaccine candidate Takeda Pharmaceutical Company
(Takeda)
and
Frazier
Healthcare Partners (Frazier) announced a collaboration to launch HilleVax, a biopharmaceutical company to develop and
commercialise
Takeda’s
norovirus
vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development
and
commercialisation
rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide commercialisation rights in Japan and
to vaccines and this collaboration allows
Lupin’s subsidiary Generic Health in tie up with Southern Cross Pharma
Takeda to focus primarily on dengue,
Generic Health, an Australia-based wholly-
COVID-19, pandemic influenza and Zika.
owned subsidiary of global pharma major
HilleVax
will
integrate
certain
Japan
development activities into its global development. Takeda remains committed
www.indiamedtoday.com
7
